Medifocus, Inc. develops and commercializes minimally invasive treatment systems and devices for the treatment of cancerous and benign tumors, including technologies for prostate diseases and breast cancer. The company owns two technology platforms: the adaptive phased array (APA) microwave focusing technology and a patented endo-thermotherapy technology platform. Its products include the Prolieve Thermodilatation System for benign prostatic hyperplasia (BPH), the APA 1000 breast cancer system, and disposable catheter kits, with Prolieve treatments offered through in-office procedures and a nationwide mobile service. The company engages in research and development collaborations with academic institutions and explores combination therapies with chemotherapy, radiation, and immunotherapy, as well as non-surgical ablation of benign breast tumors. The company serves urologic offices, physicians, and research hospitals involved in the treatment of prostate diseases and breast cancer. The company was founded in 2005 and is based in Toronto, Canada.